$27.37
4.15% yesterday
Nasdaq, Oct 01, 10:17 pm CET
ISIN
US92686J1060
Symbol
VKTX

Viking Therapeutics, Inc. Stock price

$27.37
+0.32 1.18% 1M
+3.46 14.47% 6M
-12.87 31.98% YTD
-34.63 55.85% 1Y
+24.65 906.25% 3Y
+21.65 378.50% 5Y
+21.73 385.23% 10Y
+18.41 205.47% 20Y
Nasdaq, Closing price Wed, Oct 01 2025
+1.09 4.15%
ISIN
US92686J1060
Symbol
VKTX
Industry

Key metrics

Basic
Market capitalization
$3.0b
Enterprise Value
$2.1b
Net debt
positive
Cash
$807.7m
Shares outstanding
112.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.7
Financial Health
Equity Ratio
96.9%
Return on Equity
-12.5%
ROCE
-26.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-212.4m | $-301.5m
EBIT
$-212.8m | $-313.2m
Net Income
$-171.6m | $-277.5m
Free Cash Flow
$-152.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-70.6% | -100.2%
EBIT
-70.7% | -107.5%
Net Income
-77.3% | -152.4%
Free Cash Flow
-112.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.4
Short interest
28.8%
Employees
46
Rev per Employee
$0.0
Show more

Is Viking Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Viking Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Viking Therapeutics, Inc. forecast:

21x Buy
88%
3x Hold
13%

Analyst Opinions

24 Analysts have issued a Viking Therapeutics, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Viking Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
52% 52%
-
- Research and Development Expense 155 155
79% 79%
-
-212 -212
71% 71%
-
- Depreciation and Amortization 0.42 0.42
180% 180%
-
EBIT (Operating Income) EBIT -213 -213
71% 71%
-
Net Profit -172 -172
77% 77%
-

In millions USD.

Don't miss a Thing! We will send you all news about Viking Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Viking Therapeutics, Inc. Stock News

Positive
The Motley Fool
one day ago
Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize on the trend.
Positive
Seeking Alpha
3 days ago
Viking Therapeutics trades at yearly lows despite being ahead of recently acquired competitor Metsera in the weight-loss drug race. The Metsera deal suggests up to 150% upside to Viking, especially when compared to Pfizer's $7.2 billion buyout price, including milestone CVRs. VKTX's oral and injectable weight-loss drugs show promising results, with Phase 3 trials already ongoing and potential t...
Neutral
Seeking Alpha
8 days ago
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 11:20 AM EDT Company Participants Brian Lian - President, CEO & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
More Viking Therapeutics, Inc. News

Company Profile

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Head office United States
CEO Brian Lian
Employees 46
Founded 2012
Website vikingtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today